SFJ Pharmaceuticals

SFJ Pharmaceuticals

Based: Pleasanton, CA
Raised: $35 million
Investor: Clarus Ventures

The scoop: Back in January SFJ announced a deal to collaborate with Pfizer on a late-stage study of axitinib for Asian markets. The renal cell carcinoma pact exemplifies what the company is all about. It partners with pharma and biotech on drugs that need special handling to break into Japanese and other emerging Asian markets. SFJ finances the late-stage registration study and then takes a cut of the royalties on an approval. And it has had some substantial backing from Clarus as well as Abingworth and Fintech.

SFJ Pharmaceuticals

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.